[HTML][HTML] Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu] Lu-DOTA-TATE for the treatment of neuroendocrine tumours
L Geenen, J Nonnekens, M Konijnenberg… - Nuclear medicine and …, 2021 - Elsevier
Peptide receptor radionuclide therapy (PRRT) is used for the treatment of patients with
unresectable or metastasized somatostatin receptor type 2 (SSTR 2)-expressing …
unresectable or metastasized somatostatin receptor type 2 (SSTR 2)-expressing …
[HTML][HTML] Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023
G di Santo, G Santo, A Sviridenko, I Virgolini - Theranostics, 2024 - ncbi.nlm.nih.gov
A growing body of literature reports on the combined use of peptide receptor radionuclide
therapy (PRRT) with other anti-tumuor therapies in order to anticipate synergistic effects with …
therapy (PRRT) with other anti-tumuor therapies in order to anticipate synergistic effects with …
[PDF][PDF] SNMMI procedure standard/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors
Somatostatin receptor (SSTR) imaging using PET has replaced scintigraphic imaging using
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …
Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors
H Ilhan, S Lindner, A Todica, CC Cyran, R Tiling… - European journal of …, 2020 - Springer
Abstract Introduction PET/CT using 68 Ga-labeled somatostatin analogs (SSA) targeting
somatostatin receptors (SSR) on the cell surface of well-differentiated neuroendocrine …
somatostatin receptors (SSR) on the cell surface of well-differentiated neuroendocrine …
18F-AlF-NOTA-octreotide outperforms 68Ga-DOTATATE/NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study
E Pauwels, F Cleeren, T Tshibangu… - Journal of Nuclear …, 2023 - Soc Nuclear Med
18F-labeled somatostatin analogs (SSAs) could represent a valid alternative to the current
gold standard, 68Ga-labeled SSAs, for somatostatin receptor imaging in patients with …
gold standard, 68Ga-labeled SSAs, for somatostatin receptor imaging in patients with …
[HTML][HTML] Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
A Stenvall, J Gustafsson, E Larsson, D Roth… - EJNMMI research, 2022 - Springer
Abstract Background Somatostatin receptor 68Ga PET imaging is standard for evaluation of
a patient's suitability for 177Lu peptide receptor radionuclide therapy of neuroendocrine …
a patient's suitability for 177Lu peptide receptor radionuclide therapy of neuroendocrine …
Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response—AJR Expert Panel Narrative Review
Neuroendocrine neoplasms (NENs) encompass a broad spectrum of tumors throughout the
body and range in biologic behavior from indolent to aggressive. Consequently, a wide …
body and range in biologic behavior from indolent to aggressive. Consequently, a wide …
[HTML][HTML] Peptide receptor radionuclide therapy targeting the somatostatin receptor: basic principles, clinical applications and optimization strategies
N Ahmadi Bidakhvidi, K Goffin, J Dekervel, K Baete… - Cancers, 2021 - mdpi.com
Simple Summary Peptide receptor radionuclide therapy (PRRT) is a systemic treatment
consisting of the administration of a tumor-targeting radiopharmaceutical into the circulation …
consisting of the administration of a tumor-targeting radiopharmaceutical into the circulation …
[HTML][HTML] Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide …
U Jahn, E Ilan, I Velikyan, K Fröss-Baron, M Lubberink… - EJNMMI research, 2021 - Springer
Background Low-grade neuroendocrine tumors (NETs) are characterized by an abundance
of somatostatin receptors (SSTR) that can be targeted with somatostatin analogs (SSA) …
of somatostatin receptors (SSTR) that can be targeted with somatostatin analogs (SSA) …
[HTML][HTML] Impact of cold somatostatin analog administration on somatostatin receptor imaging: a systematic review
D Morland, N Laures, EKA Triumbari… - Clinical Nuclear …, 2023 - journals.lww.com
Purpose The interactions between the administration of cold somatostatin analogs (cSAs)
and their radiolabeled counterpart remain unclear, and discontinuation before imaging is …
and their radiolabeled counterpart remain unclear, and discontinuation before imaging is …